At Raw Ventures, we are proud to share that Inflammatix, a trailblazing biotech company focused on precision medicine, has achieved FDA clearance for its TriVerity Test System.
This marks a significant milestone in healthcare diagnostics, and highlights the enormous potential of what is the first-of-its-kind molecular blood test. By distinguishing bacterial and viral infections while evaluating illness severity, TriVerity sets a new standard in emergency care diagnostics.
Sepsis and acute infections represent some of the most pressing challenges in modern healthcare. In the U.S. alone, they account for nearly half of all hospital deaths and incur $53 billion in annual costs to Medicare. Delays or mistakes in diagnosis can lead to dire outcomes, placing immense strain on patients, caregivers, and healthcare systems. TriVerity is positioned to address these challenges with its rapid, AI-driven analysis of immune response data, delivering accurate results within 30 minutes.
The test analyzes 29 gene expression patterns in the immune system to pinpoint the nature and severity of an infection, empowering emergency physicians to act swiftly and decisively. Compared to traditional diagnostics — which can take up to 24 hours — TriVerity offers a groundbreaking solution to save lives, prevent errors, and reduce unnecessary hospitalizations.
The FDA clearance of TriVerity further solidifies its importance in alleviating an overburdened healthcare system. With a streamlined hands-on time of just one minute, the system integrates seamlessly into clinical workflows, providing actionable insights at the point of care. The test has already received the Disruptive Technology Award from the American Association for Clinical Chemistry (AACC), cementing its reputation as a transformative innovation in diagnostics.
“Raw Ventures recognized Inflammatix’s potential and supported the company during its research phase to support the development of TriVerity. This investment aligns with our commitment to fostering transformative innovations that redefine healthcare standards. Our healthtech portfolio includes a wide range of companies developing disruptive solutions, all aimed at improving patient care and generating system efficiencies,” noted Victoria Palatnik, Managing Partner at Raw Ventures.
In addition to its technological breakthroughs, Inflammatix has built strong clinical partnerships with leading institutions, including Harvard, Stanford, the Mayo Clinic, and the Cleveland Clinic. These collaborations have been instrumental in validating TriVerity’s efficacy and positioning it as a trusted solution for emergency medicine.
The FDA clearance of TriVerity is a monumental achievement, and it sets the stage for its commercial launch and global impact. As healthcare systems grapple with growing demands and limited resources, innovative solutions like TriVerity offer a pathway to better outcomes for patients and providers alike.
At Raw Ventures, we are honored to support Inflammatix’s mission to revolutionize healthcare through precision medicine. By empowering healthcare professionals with cutting-edge tools, we aim to drive meaningful change in diagnostics, patient outcomes, and the overall quality of care, ultimately leading to a better, healthier world.
.jpg)
.jpg)
.png)
.png)